Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
First and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventative action and improve outcomes.
LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.
NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.
More on Ohio Pen
"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."
Journey Biosciences received CLIA certification for its lab in August 2022 and all NaviDKD blood samples are processed in this Cleveland, Ohio-based lab.
Both healthcare professionals and people with diabetes can learn more and request NaviDKD at www.journeybio.life.
More on Ohio Pen
About Journey Biosciences
Journey Biosciences is a US-based biotechnology company dedicated to fundamentally improving diabetes care. We are focused on identifying blood-based predictive biomarkers and developing clinically validated, laboratory developed tests (LDTs) that identify and rate a person's risk level for developing complications from diabetes. Learn more at www.journeybio.life.
Know Your Risk. Change Your Life. ™
To access the Journey Biosciences media kit, visit journeybio.life/media
SOURCE Journey Biosciences, Inc.
LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.
NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.
More on Ohio Pen
- Lore Link is Here to Help Organize Your Game
- Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
- 216 Marketing Launches New Website to Help Local Businesses Dominate Online in Northeast Ohio
- Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
- Powerful Stories and Shared Sisterhood Shine at "An Evening with the Author" Featuring Staci Kirk
"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."
Journey Biosciences received CLIA certification for its lab in August 2022 and all NaviDKD blood samples are processed in this Cleveland, Ohio-based lab.
Both healthcare professionals and people with diabetes can learn more and request NaviDKD at www.journeybio.life.
More on Ohio Pen
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Champions Group Expands Midwest Presence with Acquisition of McAfee Heating and Air Conditioning
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
About Journey Biosciences
Journey Biosciences is a US-based biotechnology company dedicated to fundamentally improving diabetes care. We are focused on identifying blood-based predictive biomarkers and developing clinically validated, laboratory developed tests (LDTs) that identify and rate a person's risk level for developing complications from diabetes. Learn more at www.journeybio.life.
Know Your Risk. Change Your Life. ™
To access the Journey Biosciences media kit, visit journeybio.life/media
SOURCE Journey Biosciences, Inc.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
- $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
- Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
- Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
- Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
- India's Home Textile Manufacturers See Rising Demand From US Buyers, Enabled By rivexa
- The Crave Gets Crispy: White Castle Debuts New Chicken Slider
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
- Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
- Winners Announced for Asia Pacific Business Awards 2024-2025
- Hamvay-Lang and Lampone.hu Join Forces with AIMarketingugynokseg.hu to Elevate Hungarian Lifestyle Brands on the Global Stage
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- Huntington Bancshares Incorporated Declares Cash Dividend On Its Series I Preferred Stock
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
- Rx Processing corp.com Value Proposition for Long Term Success
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI)